Saturday, March 25, 2017

Persinger vs Dawkins: The God Helmet

God On The Brain
If the abnormal brain activity of TLE patients alters their response to religious concepts, could altering brain patterns artificially do the same for people with no such medical condition? This is the question that Michael Persinger set out to explore, using a wired-up helmet designed to concentrate magnetic fields on the temporal lobes of the wearer.
His subjects were not told the precise purpose of the test; just that the experiment looked into relaxation. 80% of participants reported feeling something when the magnetic fields were applied. Persinger calls one of the common sensations a 'sensed presence', as if someone else is in the room with you, when there is none.
Horizon introduced Dr Persinger to one of Britain's most renowned atheists, Prof Richard Dawkins. He agreed to try his techniques on Dawkins to see if he could give him a moment of religious feeling. During a session that lasted 40 minutes, Dawkins found that the magnetic fields around his temporal lobes affected his breathing and his limbs. He did not find god.
Persinger was not disheartened by Dawkins' immunity to the helmet's magnetic powers. He believes that the sensitivity of our temporal lobes to magnetism varies from person to person. People with TLE may be especially sensitive to magnetic fields; Prof Dawkins is well below average, it seems. It's a concept that clerics like Bishop Stephen Sykes give some credence as well: could there be such a thing as a talent for religion?

Neuro theology

“I get attacked by everyone,” says Patrick McNamara, associate professor of neurology at Boston University and author of The Neuroscience of Religious Experience. “Atheists hate me because I’m saying religion has some basis in the brain and fundamentalist Christians hate me because I’m saying religion is nothing but brain impulses.”

God On The Brain
If the abnormal brain activity of TLE patients alters their response to religious concepts, could altering brain patterns artificially do the same for people with no such medical condition? This is the question that Michael Persinger set out to explore, using a wired-up helmet designed to concentrate magnetic fields on the temporal lobes of the wearer.
His subjects were not told the precise purpose of the test; just that the experiment looked into relaxation. 80% of participants reported feeling something when the magnetic fields were applied. Persinger calls one of the common sensations a 'sensed presence', as if someone else is in the room with you, when there is none.
Horizon introduced Dr Persinger to one of Britain's most renowned atheists, Prof Richard Dawkins. He agreed to try his techniques on Dawkins to see if he could give him a moment of religious feeling. During a session that lasted 40 minutes, Dawkins found that the magnetic fields around his temporal lobes affected his breathing and his limbs. He did not find god.
Persinger was not disheartened by Dawkins' immunity to the helmet's magnetic powers. He believes that the sensitivity of our temporal lobes to magnetism varies from person to person. People with TLE may be especially sensitive to magnetic fields; Prof Dawkins is well below average, it seems. It's a concept that clerics like Bishop Stephen Sykes give some credence as well: could there be such a thing as a talent for religion?

https://vimeo.com/54557808

LIST OF RECOMMENDATIONS to reduce conflict of interest in medical rersearch

https://www.ncbi.nlm.nih.gov/books/NBK22926/#a2001902bddd00023


OVERVIEW AND LIST OF RECOMMENDATIONS

TABLE S-1Report Recommendations in Overview

Recommendation Number and TopicPrimary Actors
General policy
3.1Adopt and implement conflict of interest policiesInstitutions that carry out medical research and education, clinical care, and clinical practice guideline development
3.2Strengthen disclosure policiesInstitutions that carry out medical research and education, clinical care, and clinical practice guideline development
3.3Standardize disclosure content and formatsInstitutions that carry out medical research and education, clinical care, and clinical practice guideline development and other interested organizations (e.g., accrediting bodies, health insurers, consumer groups, and government agencies)
3.4Create a national program for the reporting of company paymentsU.S. Congress; pharmaceutical, medical device, and biotechnology companies
Medical research
4.1Restrict participation of researchers with conflicts of interest in research with human participantsAcademic medical centers and other research institutions; medical researchers
Medical education
5.1Reform relationships with industry in medical educationAcademic medical centers and teaching hospitals; faculty, students, residents, and fellows
5.2Provide education on conflict of interestAcademic medical centers and teaching hospitals; professional societies
5.3Reform financing system for continuing medical educationOrganizations that created the accrediting program for continuing medical education and other organizations interested in high-quality, objective education
Medical practice
6.1Reform financial relationships with industry for community physiciansCommunity physicians; professional societies; hospitals and other health care providers
6.2Reform industry interactions with physiciansPharmaceutical, medical device, and biotechnology companies
Clinical practice guidelines
7.1Restrict industry funding and conflicts in clinical practice guideline developmentInstitutions that develop clinical practice guidelines
7.2Create incentives for reducing conflicts in clinical practice guideline developmentAccrediting and certification bodies, formulary committees, health insurers, public agencies, and other organizations with an interest in objective, evidence-based clinical practice guidelines
Institutional conflict of interest policies
8.1Create board-level responsibility for institutional conflicts of interestInstitutions that carry out medical research and education, clinical care, and clinical practice guideline development
8.2Revise PHS regulations to require policies on institutional conflicts of interestNIH
Supporting organizations
9.1Provide additional incentives for institutions to adopt and implement policiesOversight bodies and other groups that have a strong interest in or reliance on medical research, education, clinical care, and practice guideline development
9.2Develop research agenda on conflict of interestNIH, Agency for Healthcare Research and Quality, and other agencies of the U.S. Department of Health and Human Services
RECOMMENDATION 3.1 Institutions that carry out medical research, medical education, clinical care, or practice guideline development should adopt, implement, and make public conflict of interest policies for individuals that are consistent with the other recommendations in this report. To manage identified conflicts of interest and monitor the implementation of management recommendations, institutions should create a conflict of interest committee. That committee should use a full range of management tools, as appropriate, including elimination of the conflicting financial interest, prohibition or restriction of involvement of the individual with a conflict of interest in the activity related to the conflict, and providing additional disclosures of the conflict of interest.
RECOMMENDATION 3.2 As part of their conflict of interest policies, institutions should require individuals covered by their policies, including senior institutional officials, to disclose financial relationships with pharmaceutical, medical device, and biotechnology companies to the institution on an annual basis and when an individual’s situation changes significantly. The policies should
  • request disclosures that are sufficiently specific and comprehensive (with no minimum dollar threshold) to allow others to assess the severity of the conflicts;
  • avoid unnecessary administrative burdens on individuals making disclosures; and
  • require further disclosure, as appropriate, for example, to the conflict of interest committee, the institutional review board, and the contracts and grants office.
RECOMMENDATION 3.3 National organizations that represent academic medical centers, other health care providers, and physicians and researchers should convene a broad-based consensus development process to establish a standard content, a standard format, and standard procedures for the disclosure of financial relationships with industry.
RECOMMENDATION 3.4 The U.S. Congress should create a national program that requires pharmaceutical, medical device, and biotechnology companies and their foundations to publicly report payments to physicians and other prescribers, biomedical researchers, health care institutions, professional societies, patient advocacy and disease-specific groups, providers of continuing medical education, and foundations created by any of these entities. Until the Congress acts, companies should voluntarily adopt such reporting.
RECOMMENDATION 4.1 Academic medical centers and other research institutions should establish a policy that individuals generally may not conduct research with human participants if they have a significant financial interest in an existing or potential product or a company that could be affected by the outcome of the research. Exceptions to the policy should be made public and should be permitted only if the conflict of interest committee (a) determines that an individual’s participation is essential for the conduct of the research and (b) establishes an effective mechanism for managing the conflict and protecting the integrity of the research.
RECOMMENDATION 5.1 For all faculty, students, residents, and fellows and for all associated training sites, academic medical centers and teaching hospitals should adopt and implement policies that prohibit
  • the acceptance of items of material value from pharmaceutical, medical device, and biotechnology companies, except in specified situations;
  • educational presentations or scientific publications that are controlled by industry or that contain substantial portions written by someone who is not identified as an author or who is not properly acknowledged;
  • consulting arrangements that are not based on written contracts for expert services to be paid for at fair market value;
  • access by drug and medical device sales representatives, except by faculty invitation, in accordance with institutional policies, in certain specified situations for training, patient safety, or the evaluation of medical devices; and
  • the use of drug samples, except in specified situations for patients who lack financial access to medications.
Until their institutions adopt these recommendations, faculty and trainees at academic medical centers and teaching hospitals should voluntarily adopt them as standards for their own conduct.
RECOMMENDATION 5.2 Academic medical centers and teaching hospitals should educate faculty, medical students, and residents on how to avoid or manage conflicts of interest and relationships with pharmaceutical and medical device industry representatives. Accrediting organizations should develop standards that require formal education on these topics.
RECOMMENDATION 5.3 A new system of funding accredited continuing medical education should be developed that is free of industry influence, enhances public trust in the integrity of the system, and provides high-quality education. A consensus development process that includes representatives of the member organizations that created the accrediting body for continuing medical education, members of the public, and representatives of organizations such as certification boards that rely on continuing medical education should be convened to propose within 24 months of the publication of this report a funding system that will meet these goals.
RECOMMENDATION 6.1 Physicians, wherever their site of clinical practice, should
  • not accept of items of material value from pharmaceutical, medical device, and biotechnology companies except when a transaction involves payment at fair market value for a legitimate service;
  • not make educational presentations or publish scientific articles that are controlled by industry or contain substantial portions written by someone who is not identified as an author or who is not properly acknowledged;
  • not enter into consulting arrangements unless they are based on written contracts for expert services to be paid for at fair market value;
  • not meet with pharmaceutical and medical device sales representatives except by documented appointment and at the physician’s express invitation; and
  • not accept drug samples except in certain situations for patients who lack financial access to medications.
Professional societies should amend their policies and codes of professional conduct to support these recommendations. Health care providers should establish policies for their employees and medical staff that are consistent with these recommendations.
RECOMMENDATION 6.2 Pharmaceutical, medical device, and biotechnology companies and their company foundations should have policies and practices against providing physicians with gifts, meals, drug samples (except for use by patients who lack financial access to medications), or other similar items of material value and against asking physicians to be authors of ghostwritten materials. Consulting arrangements should be for necessary services, documented in written contracts, and paid for at fair market value. Companies should not involve physicians and patients in marketing projects that are presented as clinical research.
RECOMMENDATION 7.1 Groups that develop clinical practice guidelines should generally exclude as panel members individuals with conflicts of interest and should not accept direct funding for clinical practice guideline development from medical product companies or company foundations. Groups should publicly disclose with each guideline their conflict of interest policies and procedures and the sources and amounts of indirect or direct funding received for development of the guideline. In the exceptional situation in which avoidance of panel members with conflicts of interest is impossible because of the critical need for their expertise, then groups should
  • publicly document that they made a good-faith effort to find experts without conflicts of interest by issuing a public call for members and other recruitment measures;
  • appoint a chair without a conflict of interest;
  • limit members with conflicting interests to a distinct minority of the panel;
  • exclude individuals who have a fiduciary or promotional relationship with a company that makes a product that may be affected by the guidelines;
  • exclude panel members with conflicts from deliberating, drafting, or voting on specific recommendations; and
  • publicly disclose the relevant conflicts of interest of panel members.
RECOMMENDATION 7.2 Accrediting and certification bodies, health insurers, public agencies, and other similar organizations should encourage institutions that develop clinical practice guidelines to adopt conflict of interest policies consistent with the recommendations in this report. Three desirable steps are for
  • journals to require that all clinical practice guidelines accepted for publication describe (or provide an Internet link to) the developer’s conflict of interest policies, the sources and amounts of funding for the guideline, and the relevant financial interests of guideline panel members, if any;
  • the National Guideline Clearinghouse to require that all clinical practice guidelines accepted for posting describe (or provide an Internet link to) the developer’s conflict of interest policies, the sources and amounts of funding for development of the guideline, and the relevant financial interests of guideline panel members, if any; and
  • accrediting and certification organizations, public and private health plans, and similar groups to avoid using clinical practice guidelines for performance measures, coverage decisions, and similar purposes if the guideline developers do not follow the practices recommended in this report.
RECOMMENDATION 8.1 The boards of trustees or the equivalent governing bodies of institutions engaged in medical research, medical education, patient care, or practice guideline development should establish their own standing committees on institutional conflicts of interest. These standing committees should
  • have no members who themselves have conflicts of interest relevant to the activities of the institution;
  • include at least one member who is not a member of the board or an employee or officer of the institution and who has some relevant expertise;
  • create, as needed, administrative arrangements for the day-to-day oversight and management of institutional conflicts of interest, including those involving senior officials; and
  • submit an annual report to the full board, which should be made public but in which the necessary modifications have been made to protect confidential information.
RECOMMENDATION 8.2 The National Institutes of Health should develop rules governing institutional conflicts of interest for research institutions covered by current U.S. Public Health Service regulations. The rules should require the reporting of identified institutional conflicts of interest and the steps that have been taken to eliminate or manage such conflicts.
RECOMMENDATION 9.1 Accreditation and certification bodies, private health insurers, government agencies, and similar organizations should develop incentives to promote the adoption and effective implementation of conflict of interest policies by institutions engaged in medical research, medical education, clinical care, or practice guideline development. In developing the incentives, these organizations should involve the individuals and the institutions that would be affected.
RECOMMENDATION 9.2 To strengthen the evidence base for the design and application of conflict of interest policies, the U.S. Department of Health and Human Services should coordinate the development and funding of a research agenda to study the impact of conflicts of interest on the quality of medical research, education, and practice and on practice guideline development and to examine the positive and negative effects of conflict of interest policies on these outcomes.

Is coconut oil like mother's milk?

Certain saturated fats are extremely healthy and even essential to good health...
such as coconut oil.
 For a number of years, coconut oil has been vilified by the medical health authorities due to its saturated fat content
 but coconut oil is unique in its structural makeup.
 It is not only the highest source of saturated fats (92 percent), yet included in that number are the medium-chain triglycerides (MCTs), which are extremely beneficial to the body.
 In addition, approximately 50 percent of these MCTs are made up of lauric acid, the most important fatty acid in building and maintaining the body's immune system. 

The only other source of lauric acid found in such high concentrations is mother's milk.

Maintaining energy homeostasis

Maintaining energy homeostasis and storing calories when food is available is fundamental for survival. In the modern world, a disruption in energy balance from an increase in calories consumed compared to energy expended is more common than a food scarcity. Unfortunately, over nutrition can lead to obesity, diabetes, nonalcoholic fatty liver disease, colon cancer and many other significant chronic diseases. Clearly, obesity is an increasing public health problem, as now more than two-thirds of the US population is now overweight or obese and parallel occurrences are being seen virtually worldwide
All species have faced the challenge of adapting to scarcity of food and thus strategies to deal with major discrepancies in food availability have evolved to allow propagation of the species. It is clear that the nervous system is the ultimate regulator of these adaptive mechanisms. The central nervous system’s role in regulating energy balance in a coordinated fashion with the constantly adjusting energy intake, expenditure and storage was first demonstrated by early studies in which selective surgical lesions of certain hypothalamic areas was found to result in extreme obesity in rats




Neurons in the hypothalamus including those in the arcuate nucleus are targets of a number of key hormones and metabolic cues. These neurons target several downstream sites to influence complex circuits in the central nervous system (CNS). The downstream effector circuits mediate the coordinated autonomic, behavioral, and endocrine responses to changing levels of metabolic signals. Diminished responses of first order neurons such as those in the arcuate nucleus may contribute to the pathogenesis of obesity and type II diabetes. This includes increased body weight, uncontrolled glycemia, and altered insulin secretion and insulin sensitivity in target tissues such as liver, adipose tissue, pancreas, and skeletal muscle. Thus, the CNS not only regulates food intake and body weight, but also plays a key role in regulating glucose homeostasis in peripheral tissues.

vagus nerve serves as a critical link between changing energy availability and coordinated control of glucose homeostasis The nervous system senses peripheral metabolic cues, resulting in coordinated energy homeostasis.  

Vitamins and minerals Not New wine in old bottle but old wine in New Bottles ?

Vitamins and minerals
 are necessary cofactors for hundreds of biochemical reactions that are essential for proper bodily function. Patients with gastrointestinal and liver diseases have disruptions in their physiology that place them at risk for numerous vitamin and mineral deficiencies. The clinician caring for patients with alimentary and hepatic disorders should know the risk of vitamin and mineral deficiency (or deficiencies), their potential ramifications, how to recognize their signs and symptoms, utilize confirmatory diagnostic testing, and become familiar with corrective supplementation and monitoring guidelines. Many individuals with digestive disorders consume vitamins and minerals above the dietary reference intake recommendation and are at risk for toxicity. 

 I will present a comprehensive review of the vitamins and minerals, their actions, dietary sources, risk factors for deficiency, signs and symptoms of deficiency, and toxicity and treatment in a number of blogs over the next few months  

More Medical Jargon

Term 
Definition

Clinical practice guidelines
 Systemically developed statements to assist practitioner and patient decisions about appropriate healthcare for specific clinical circumstances
CMS 
Center for Medicare and Medicaid Services
Cost-effectiveness analysis 
An analysis performed to measure the cost incurred in relationship to the benefit achieved and may be used to compare strategies that are expected to yield different outcomes
Cost–benefit analysis
A cost-effectiveness analysis in which all outcomes are expressed in monetary terms
Cost–consequence analysis
 An analysis in which the components of costs and consequences of competing strategies are presented without aggregation of results
 Cost-minimization analysis
 An analysis performed to calculate the least expensive manner in which to treat a specific disorder

Cost–utility analysis
 A cost-effectiveness analysis that varies the outcome to reflect patient preferences associated with each health state
Dominant strategy 
A strategy that is both more effective and less expensive than a comparator
Costs 
The resources required to provide a particular service that represent the foregone opportunity to provide another service
 Effectiveness
 Outcomes achieved in “real-life” settings using patients who may not have been represented in clinical trials, under varied management conditions
 Efficacy 
Outcomes achieved in research settings using idealized subjects under optimal conditions
GRADE 
Grading of Recommendations Assessment, Development and Evaluation: framework to develop high-quality guidelines
 HIPAA
 Health Insurance Portability and Accountability Act
ICER
 Incremental cost-effectiveness ratio: the additional cost incurred by providing an alternative strategy in order to achieve increased effectiveness
Metaanalysis 
Quantitative approach for systematically assessing the results of previous research to arrive at conclusions about the body of research
Mobile health (mHealth)
 The use of mobile electronic devices such as pagers, cell phones, smartphones, laptops, tablet/pad computers, and biosensors to collect, analyze, and/or deliver health information
NQF
 National Quality Forum
 PICO
 Population; intervention; comparator; outcome: format to describe the clinical question to be answered by a guideline
QALY 
Quality-adjusted life year
 RCT
 Randomized clinical trial
 Systematic review 
A process to examine a clearly formulated clinical management question using explicit methods to identify, select, and critically appraise relevant research, and to collect and analyze data from included studies

Friday, March 24, 2017

IVF vacation

The brokers sell reproductive travel by the guarantee not of a successful cycle of IVF but of a vacation. One blog reads: It sounds crazy, but John and I agree that it wouldn’t have been devastating if we failed our first trip, because we would get to go back and see everyone and everything again. Oh yeah, and shop more! When we had failed cycles in the States (we had many, many failures here) we felt like our money just went to waste. It just evaporated. Even if we didn’t get pregnant on our first try in the Czech Republic, our money gave us a great vacation and memories. The Czech Republic is a very easy and beautiful country to travel in, the locals are friendly, a lot of people speak English, and the food is great. Petra will guide you through all the travel and even schedules massages!!

IVF Holidays in Czechoslovakia

Like many North American couples that marry for a second or third time, Tom had a teenage son from a previous marriage and had had a vasectomy. Younger than Tom, Hana wanted her own children, so Tom underwent a vasectomy reversal, which alone can be costly. However, their doctor said they would still need to do IVF. When they were quoted a price of more than $10,000 for treatment in the United States, they were devastated. Like the couples we met in chapter 1, they knew Tom’s middle-class salary alone would not be enough to pay for treatment. Hana decided to visit a Czech clinic during one of her annual visits home. 52 | Virtual Communities and Markets Luckily, Hana’s first cycle of IVF led to the birth of twin girls. Buoyed by their success, Tom and Hana talked about helping other lowermiddle-class North Americans travel to the Czech Republic, where they could take advantage of the lower prices of Czech reproductive medicine. Four months pregnant, Hana began to make arrangements with several places of accommodation and the clinic where she had been treated. When Dr. R., head of the clinic, narrated the beginning of his relationship with IVF Holiday, he said Hana was very “wise” in creating her website, which she called “IVF Holiday.” Suddenly, patients diligently conducting research online would land upon this broker website, where they are greeted by a picture of Tom and pregnant Hana, the happy ending to their infertility story implicit from the first glance at her expanding belly. Images of postage stamps and European travel destinations adorn the background of the website, alongside pictures of beautiful castles, lush scenery, and the most effective testimonial of Czech IVF: a picture of Tom and Hana’s twins smiling at the bottom of their personal story. In the first few months of their business, Hana was approached by a woman, Petra, who was another Czech married to a North American. Petra proffered a partnership, which Tom and Hana declined. In May 2006, they were appalled to discover a website, “IVF Choices,” that mimicked their business model. Petra also worked with a clinic in Moravia. Like Hana, Petra networked with various hotels in Brno and contracted with an apartment her mother managed. Unlike Hana, however, she earned an exclusive contract with the clinic, which benefited tremendously from gaining foreign clientele. The sudden appearance of these two broker companies whose business models mirrored each other reflects the extent to which this medical tourism industry is highly competitive.


In January 2006, IVF Holiday trademarked its website and began arranging travel to Zlín, Czech Republic. The beginning was slow going until the company’s first clients gave birth; their successful cycle and testimonial propelled the business. By 2008, IVF Holiday was sending five to fourteen couples to the clinic each month, with business steadily growing for several years. The company advertised on Yahoo and Google and received national attention from news companies, anthropologists, blogs, and many patients. In these first few years, any North American couple that wanted to go to the Czech Republic for IVF had to use the services of IVF Holiday. Broker rates varied from $399 to $3,000, and couples could choose from different packages and services. Once the business had had enough successful cycles, clients provided testimonials, which became the mainstay in terms of advertising fertility tourism.

Infertility lamenters

Furthermore, just as ARTs can be both empowering and disempowering for infertile women, joining these biosocial worlds of support can also be Janus-faced. Many brokers, doctors, and husbands expressed concern about the amount of time women spent online. As we talked, Daniel, from Los Angeles, struggled slightly as he tried to articulate the complicated nature of these sites. He described the two sides of online forums: “There’s a lot of hope on there and advice on the forum, because it’s all a bunch of women wanting themselves and other women to succeed. There is that sort of negative pall that sort of hangs over the whole thing of people that tried it and it didn’t work out. That’s not something that I want to talk about.” Women who initially land upon websites of support may “lurk” before joining. A woman’s level of participation will ebb and flow as she moves along her journey. In her years of being a broker, Petra had become critical of the forums for being full of “too much estrogen,” and Jenny, though she championed the use of Google, characterized the women online as “lamenters.” Here, we note that women who participate in virtual communities walk a fine line and may face approbation if they participate too heavily. It is as if women are expected to continue to work hard, go online to seek information and resources, yet never wallow or succumb to the depressing side of infertility. There is a femininity/fertility police that is enforcing gender norms that urge women to maintain a semblance of hope for a family. Given the tidal nature of women’s participation, fertility threads will split, and some blogs fall into favor while others fizzle out. When I asked Petra of IVF Choices which sites she would recommend, she said, “It changes so often. Something that I found a few months ago is not there, and something else is not there. So I wouldn’t recommend a specific site to go to, but always try to do a fresh search.” Ultimately, it is through such blogs and support groups that women learn about reproductive travel. One husband joked that his wife had found out about reproductive travel on eBay, which highlights the global, consumer framework of fertility medicine. Once a woman hears about this phenomenon, she will try to learn more.

Virtual Communities and Markets

Virtual Communities and Markets


After the IVF Vacation experience, I cannot understand why anyone would opt to pay $30,000 plus dollars for the U.S.A. IVF donor option when they will receive the same level of medical support in the Czech Republic plus have a wonderful vacation for less than half the cost of the U.S. IVF donor program! —Anonymous blog

As we have seen, lower-middle-class infertile couples are often angry and frustrated by the high-priced North American “baby business” and begin to question the medical care provided by doctors. Jenny, disillusioned by doctors’ greed and failure to care, turned to the Internet. She told me: “We decided there has to be some other option, somebody’s not telling us something. So [we] start Googling. Unfortunately for doctors in the U.S., we have the Internet now. So patients can take matters into their own hands. They used to be able to tell us whatever and we’d heed it. Now we don’t need to anymore. Now we can get our own information and do things for ourselves.” When a person like Jenny goes online seeking information related to a medical issue, she is embracing a neoliberal model of health care.1 This model includes the following elements: no government regulation or offering of public services, plus a freeing of borders and constraints to allow for the mobility of capital, people, and services on a global scale. This model of profit-driven health care has been exported around the world, whereby health is viewed as a commodity (Whittaker, Manderson, and Cartwright 2010:337). As described by Stone, “Global capitalism has meant an increasing linking of local, small-scale economies into a broader international economy dominated by multinational corporations. These corporations are oriented toward profits, economic growth, and the commoditization of more and more goods and services.

IVF Tourism and the Reproduction of Whiteness

Fertility Holidays

IVF Tourism and the Reproduction of Whiteness
Amy Speier
Publication Year: 2016
Each year, more and more Americans travel out of the country seeking low cost medical treatments abroad, including fertility treatments such as in vitro fertilization (IVF). As the lower middle classes of the United States have been priced out of an expensive privatized “baby business,” the Czech Republic has emerged as a central hub of fertility tourism, offering a plentitude of blonde-haired, blue-eyed egg donors at a fraction of the price.
 
Fertility Holidays presents a critical analysis of white, working class North Americans’ motivations and experiences when traveling to Central Europe for donor egg IVF. Within this diaspora, patients become consumers, urged on by the representation of a white Europe and an empathetic health care system, which seems nonexistent at home. As the volume traces these American fertility journeys halfway around the world, it uncovers layers of contradiction embedded in global reproductive medicine. Speier reveals the extent to which reproductive travel heightens the hope ingrained in reproductive technologies, especially when the procedures are framed as “holidays.” The pitch of combining a vacation with their treatment promises couples a stress-free IVF cycle; yet, in truth, they may become tangled in fraught situations as they endure an emotionally wrought cycle of IVF in a strange place.
 
Offering an intimate, first-hand account of North Americans’ journeys to the Czech Republic for IVF, Fertility Holidays exposes reproductive travel as a form of consumption which is motivated by complex layers of desire for white babies, a European vacation, better health care, and technological success.


Acknowledgments ix Introduction 1 1. From Hope to Alienation: North Americans Enter the Baby Business 17 2. Virtual Communities and Markets 41 3. Intimate Labor within Czech Clinics 63 4. Contradictions of Fertility Holidays 101 5. Separate but Connected Paths 118 Conclusion: An Eye to the Future 143 Notes 151 Bibliography 153 Index 163 About the Author


Introduction In my small bed-and-breakfast room in Moravia, I interviewed April, a blonde, blue-eyed music educator, and her husband, Larry, a teddy bear of a man. The two sat side by side, squished on my maroon leather loveseat, as I perched across from them on the edge of my bed. They took turns answering my questions about their experience with infertility and the world of assisted reproduction. The ease and flow of the conversation indicated a close, loving relationship and their mutual support. High school sweethearts, April and Larry were ready to have a baby once they had been married several years. After a year of seeing what would happen when they stopped using contraception, they began to wonder. April started charting her temperature to find out when she ovulated, and they began having “timed relations.” After another six months of making a more concerted effort, April decided to speak to her ob-gyn. Sadly, they learned that Larry had “weak” sperm, and they were referred to a fertility specialist. April and Larry were frustrated at what they felt was an interruption in their planned life cycle. Larry’s low sperm count affected his sense of masculinity, while April panicked because she had always wanted children. As they watched the families of their close friends grow, they felt increasingly isolated in their struggles. April joined an online support group for infertility called RESOLVE, where she basked in the support and information shared among women. At the fertility clinic, the doctor suggested April and Larry begin with noninvasive intrauterine injections (IUIs) to give Larry’s sperm a “jump start.” They underwent three cycles of IUI, at which point they decided that April should take fertility drugs to help stimulate the growth of more eggs, aiming to increase chances for conception. After another three unsuccessful rounds of IUI, their doctor suggested they begin to think seriously about in vitro fertilization (IVF). The doctor sent April and Larry to the clinic’s business office, which handled payment issues. The woman at the business office tallied the 2 | Introduction costs of future office visits at $300 per visit, the various procedures they would need, such as intracytoplasmic sperm injection (ICSI),1 and costly medications. With only partial insurance coverage, they found themselves having to pay for nearly everything out of pocket. The price tag kept climbing until it reached $15,000. The two of them decided to put off renovating their bathroom and dipped into their savings. When their first cycle was unsuccessful, the doctor suggested they try IVF using donor egg, which again increases the chance of conception. But the price tag for IVF using an egg donor skyrocketed to nearly $35,000. Their jaws dropped, and they felt like a concrete road barrier had crashed in front of them, ending all chances for a semibiological family. They knew they could not afford it. The clinic suggested that they remortgage their house. Once again, April, heartbroken, turned to her online support group. A fellow RESOLVE member told April about a company called IVF Holiday that was arranging IVF with donor egg in the Czech Republic at dramatically lower prices. At first, April thought traveling so far away was a crazy idea, and she dismissed it immediately. But she kept returning to the IVF Holiday website, reading testimonials about couples’ successful IVF cycles. The website proffered images of smiling white babies as well as beautiful European landscapes, claiming couples would have “plenty of time to see exactly what you want and leave with wonderful experiences.” One day she contacted IVF Holiday, whose owners gave her contact information for previous clients, whom she called to speak with about their experiences. April knew she could convince Larry to go abroad, simply because the price would be a third of the price of an IVF cycle at home. Also, they had always talked about traveling around Europe. Once again, April and Larry began to be excited about the prospect of trying to have a baby. April sent her medical history to the IVF broker, who arranged all their clinical appointments. Larry and April were assured they would be picked up at the airport and taken to a small town in Moravia where the clinic was located. They decided to stay at a pension, a small bed-andbreakfast. April and Larry were stunned by the dramatically lower costs of the medications they received in the mail from the Czech clinic. As April began her medications, Larry perused travel websites, fantasizing Introduction | 3 about trips to Prague or Vienna with thoughts of romantic castles on his mind. They were riding on clouds of hope. Early in June 2010, April and Larry flew to Prague, Czech Republic, where they met another couple—Jessica and Doug—who arrived the same day, rode with them to the eastern Czech town, and stayed in the same small, intimate pension, where they ate breakfast together every day for three weeks. During their stay in the Czech Republic, April and Jessica visited the clinic together and even had their embryo transfers the same day. The two couples shared stories of trying to get pregnant as they explored local attractions together. April and Larry were pleasantly surprised by the friendly owners of the bed-and-breakfast, a small family whose kindness and generosity were unsurpassed. They felt respected by the Czech doctors, whose names seemed unpronounceable but who spent a lot of time answering their questions, never rushing them. They felt like they had a navigator in their IVF brokers, who showed they truly cared by checking on them while they were in the Czech Republic. Everyone seemed to want April to get pregnant. Larry surprised April by booking a four-star hotel in Prague, directly under the castle, as a last splurge before heading home, hoping for pregnancy. They dined on the rooftop, serenaded by a quartet playing Dvořák and Smetana. April felt like a queen and was optimistic. She thought the music must be soothing to the two embryos recently transferred into her uterus. April and Larry were sad to say good-bye to Jessica and Doug, and the women vowed to stay in touch and keep track of one another’s progress. They joked that maybe their roads would cross once again if they decided to return to the Czech Republic for another round of IVF, trying for siblings of their future babies. Sadly, April and Larry’s cycle was not successful this time,2 although Jessica and Doug welcomed twin boys the following spring. Fertility Tourism? This is the story of a North American couple I met, who, like so many others, encountered financial barriers to accessing fertility treatment at home. Reproductive travel, what Briggs (2010:51) has referred to as “offshore (re)production,” has grown as one of the main forms of medical 4 | Introduction travel due to the high cost of infertility treatment in the United States (Spar 2006; C. Thompson 2005); the unavailability of gamete donors, as in Germany (Bergmann 2011); strict regulatory laws, as in Italy (Zanini 2011); or a lack of general access to biomedical technologies, as in Nigeria (Pennings 2002). Given the global scope of reproductive travel, there is a “wide range of very different forms of regulation, bans, and approvals as well as considerable differences in clinical practice, public or private financing, and moral or ethical reasoning” (Knecht, Klotz, and Beck 2012:12). Scholars have debated the terminology of fertility tourism, referring to it as “reproductive tourism,” “procreative tourism,” or “cross-border reproductive care” (Gürtin and Inhorn 2011; Whittaker and Speier 2010). Franklin has called it “reproductive trafficking” (2012:34), and many qualify the word “tourism” with quotation marks. The majority of scholars find the term problematic, since it connotes pleasure “and thus trivializes fertility problems” (Knoll 2012:265). Some argue that in the case of same-sex couples or unmarried individuals the label “reproductive exiles” is more appropriate, since they are forced to seek treatment abroad (Matorras 2005; Inhorn and Patrizio 2009). Most assume it is the wealthy who can afford to travel abroad for medical care, yet Elisa Sobo and her collaborators claim that “medical travelers seeking biomedical treatment overseas may be disproportionately representative of the working poor” (2011:133). Admittedly, because infertile couples are otherwise healthy, “IVF treatment can lend itself to a combination of treatment and tourism between appointments” (Whittaker and Speier 2010:370). I argue that since IVF Holidays are branded as vacations, the “tourism” terminology should be retained. Knoll is in agreement when she writes, “From my anthropological perspective, tourism is an analytic term that captures the complexities of various kinds of peaceful movements across borders” (2012:265) and, more specifically, that “the notion of reproductive tourism therefore captures new forms of choice and consumerism in health care that tend to undermine the distinction between tourism and health care” (267). Whatever term used, it is a phenomenon enabled by globalization and the commercialization of reproductive medicine (Gürtin and Inhorn 2011). Introduction | 5 The multitude of reproductive travel routes is “varied”; a recent symposium on cross-border reproductive care includes twenty-two nations and five continents (Gürtin and Inhorn 2011). Ironically, the United States is a destination site because of the scant amount of regulation, though laws do vary from state to state. California is a favorite destination for gay couples, as well as for surrogacy—but it is largely for the wealthy elite, with the cost of treatments estimated at $100,000. Typically, however, destination sites of fertility travel can offer medical infrastructure and expertise, certain regulatory frameworks, and lower wage structures, which allow reproductive technologies to be performed at competitive, lower costs. In addition to a sense of cultural familiarity (which may mean a common language), patients are often seeking specific services such as sex selection, surrogacy, or commercial ova donation (Blyth and Farrand 2005). Given the global scope of reproductive tourism, as well as the methodological complexities of tracing these travel routes, data are fragmented regarding this “patchwork of widely diverging national laws” (Klotz and Knecht 2012:284). It is impossible to know how many people are traveling internationally for this type of care (Nygren et al. 2010). There are well-established “hubs” of reproductive tourism. India is known for its surrogacy market, offering some of the most affordable cycles at $20,000. Thailand is a hot spot for couples wanting to select the sex of their offspring using preimplantation genetic diagnosis (PGD) on embryos (Whittaker 2011). Other areas of the globe involved in reproductive travel are South Africa, Mexico, and the United States. A reported 24,000 to 30,000 cycles of IVF are performed in Europe each year, serving 11,000 to 14,000 patients (Inhorn and Patrizio 2012). The Czech Republic is emerging as one of the top European destinations for reproductive travel because, unlike most countries, it offers anonymous egg donation. Spain is the largest and oldest provider of reproductive medicine to foreign patients, and the Czech industry largely mimics the Spanish model in terms of regulations. However, the Czech Republic presently has “gaps” in regulations. Bergmann has named these “two of the main European destinations for egg donation” (2012:333). There are 200 clinics in Spain, which attests to the fact that reproductive travel has been an established industry for much longer than 6 | Introduction in the Czech Republic. In addition, since 2006 Spanish clinics may not discriminate against any person as a potential client, whereas the 43 Czech clinics will treat only married heterosexual couples. Because the Czech Republic’s population is largely atheist, limiting treatment to couples is related not to religious belief but rather to heteronormative state policies. Czech clinical websites advertise in English, German, Italian, and Russian, promising a ready availability of student egg donors with only a three-month waiting period. The Czech reproductive medical field is profiting from its lower price structure and liberal legislation stipulating that sperm and egg donation must be voluntary and anonymous. Donors cannot be paid for their eggs but are offered attractive “compensatory payments” of approximately 1,000 euros ($1,134) for the discomfort involved in ovarian stimulation and oocyte retrieval. For North American patients traveling to the Czech Republic during the time of this research, treatment for IVF was $3,000, and for an egg donor cycle the cost was $4,000. North Americans spend, on average, $10,000 for the entire trip to the Czech Republic. In comparison, a round of IVF with egg donation in the United States costs between $25,000 and $40,000. The European reproductive medical industry oriented toward foreign patients seems to be expanding eastward, as several Eastern European countries have recently emerged in this global market with slight differences in regulation. The Ukraine allows for “virtually everything,” including surrogacy, while Bulgaria does not have legislation about surrogacy yet (Global IVF 2012). Like the Czech Republic, Hungary restricts clients to heterosexual couples. However, if a single woman suffers from a medical condition like cancer that requires chemotherapy, which will likely lead to infertility, a clinic in Hungary will allow her to undergo IVF. Romania used to provide gamete donation for foreigners, until the practice was outlawed in 2008 (Nahman 2013). The global market of reproductive technologies as painted here obviously offers a vast array of choices for patients aiming to create a family using reproductive technologies. As North Americans are shopping the globe for different destination countries, they are acting as consumers with respect to their health care. One objective of this book is to trace North American quests for parenthood along this global care route to the Czech Republic. Introduction | 7 Most assume that this phenomenon of reproductive travel needs no further explanation beyond cost-effectiveness. However, as consumers, North Americans do not decide to travel abroad only for lower prices: indeed, the Czech Republic does not offer the lowest prices in the market. Thus, much more needs to be understood about this recent phenomenon because it reveals the complex interplay between global neoliberal shifts in health care and individual experiences of reproductive travel. The existence of the global care chain between North America and the Czech Republic can be credited to two entrepreneurial Czech women, Hana and Petra, both of whom married American men and subsequently suffered infertility. Both transnational couples had been “return reproductive travelers” (Inhorn 2011) to their Moravian hometowns in the Czech Republic, where they had access to state-funded assisted reproductive technologies (ARTs). After receiving treatment, each woman created an IVF broker agency, hoping to help other North Americans unable to afford treatment in the United States. These fertility brokers, who began offering “fertility holidays” in 2006, are important new actors at the center of reproductive travel. Websites of IVF brokers must be considered “political economies of hope” (Rose and Novas 2005). Political economies of hope, which are propelled by organizations of infertile patients, extend the “hope” already embedded in reproductive technologies (Franklin 1997a). Brokers lure North Americans who desperately want a baby with the promise of white donors, a European vacation, and top-notch health care. Roughly two-thirds of the twenty-nine couples I met in the Czech Republic were pursuing IVF with an egg donor, rather than IVF with their own eggs. In addition, North Americans are seeking a European vacation alongside excellent health care. Doctors who care are painfully lacking in the United States’ profit-hungry “baby business” (Spar 2006). Couples who choose to follow the path of reproductive travel make decisions based on complex notions of kinship, health care, and what constitutes a vacation. However, hope is the underlying basis of all of these factors. Typically, North Americans traveling to the Czech Republic for in vitro fertilization are seeking gamete donation that will assure a biological connection with one parent and at least a physical resemblance to the other parent. We can distinguish these couples from those seeking children through international adoption from a country with children 8 | Introduction of markedly different ethnicity (Jacobson 2008). North Americans traveling to the Czech Republic are almost always seeking “white” babies from Czech egg or sperm donors (see also Kahn 2000:132; Nahman 2008). In using the term “white” I am referring to the dominant sociocultural logic of U.S. race and color lines. North Americans use the term “white” as if there is one variant of “white” (Rothman 2005:79). Racial categories label sets of physical characteristics that we can locate on the body (Rothman 2005:90). Notions of white have often been tied to ideas of purity, but in these cases whiteness is also tied closely to notions of relatedness. This desire for “white” babies reflects an “appeal of European heritage” (Nash 2003:184). Scholars of international adoption to Russia and Eastern Europe have written about the ways that North Americans assume they can forge a deeper kinship connection through “sharing whiteness with a child” (Jacobson 2008:42). Jacobson further elaborates that whiteness is often assumed to be stable and passed through bloodlines (2008:63). North Americans traveling to the Czech Republic are trying to ensure racial stability for their families. A Global Marketplace of Health Care A global reproductive tourism industry indicates shifts in global policies of health care. Whittaker bears witness to “neoliberal readjustments of societies across the world to meet the demands of economic globalization” (2008:273). Countries across the globe have been shifting away from nationalized systems whereby the government assumes responsibility in providing universal health care to all citizens. Transitioning toward neoliberal health care models is often touted for its efficiency. The way patients make the decision to travel abroad for health care reflects a strengthening of the global, neoliberal model of consumer health care. In this model, patients essentially become consumers “choosing” from various possible treatment options. As consumers believe themselves to be free actors, they are simply choosing from various possible menu items. Responsibility has fallen on them as ostensibly free actors in a global medical marketplace. As I traced North American fertility journeys halfway around the globe, I uncovered layers of contradiction embedded in global repro- Introduction | 9 ductive medicine. Scholars have already shown how reproductive technologies are “hope” technologies (Franklin 1997a) that both empower women, by offering new opportunities to try to have a baby, and disempower them, by pressuring women to continuously subject their bodies to these medical technologies with no end point in sight. Medical anthropologists have often examined the power inherent in biomedicine, and feminist scholars note further the power embedded in reproductive medicine (Martin 1989; Rapp 2000; Davis-Floyd 2003). Many anthropologists have written about medicalization as disempowering to women, in that it assumes management over their bodies (Martin 1989; Turiel 1998). Even further, Sandelowski (1991) has written of how the promises of reproductive technologies often “compel” women to keep trying. However, even though reproductive medicine may in fact disempower some women, Sundby (2002) has insisted on the recognition of the empowering nature of reproductive technologies. Though these technologies tend to be distributed unevenly, they do offer couples a chance to conceive. Feminist theory has often failed to consider the actual experiences of women suffering infertility (Sandelowski 1990). This book explores the extent to which reproductive technologies remain complicated and even more ambiguous in a foreign setting. This book focuses on the multiple contradictions that occur as reproductive travelers embrace an ideological vision of vacation proposed by brokers. These contradictions, largely embedded in the term “IVF holiday,” point to the tensions and disjunctures of a global marketplace for health care. As consumers, these patients must make difficult decisions regarding their health, and medical tourism brokers have packaged fertility holidays to aid in their decision making. This volume argues that reproductive travel exacerbates the hope embedded in reproductive technologies, especially when they are marketed as holidays. It frames reproductive travel as a form of consumption motivated by complex layers of desire for white babies, a European vacation, better health care, and technological success. Each of these desires is further mired within its own contradictions. The volume demonstrates that reproductive tourists must be diligent consumers within a global neoliberal market of health care that perpetuates stratified reproduction. 10 | Introduction Methods I first heard of IVF Holiday in 2008, when a friend sent me a link to the company’s website. I consider my initial foray into the world of reproductive travel somewhat akin to how most North Americans learn about it: through Google searches and word of mouth. This research is based on a multisited project conducted in North America and the Czech Republic between 2010 and 2012. It is the first in-depth ethnographic study of North American reproductive travel to the Czech Republic from the consumer’s point of view. I gathered data through participant observation, surveys, focus groups, and interviews with the three primary social actors involved in the reproductive travel industry: North American reproductive travelers, Czech reproductive medicine providers, and brokers. Ethnographic research at two reproductive clinics in the Czech Republic, as well as with patient tourists after they returned from their travels, provides insight into their complex behaviors, motivations, and experiences of reproductive travel. Anthropologists have discussed the logistical, ethical, and technical difficulties of gaining access to infertile couples, especially those who travel abroad seeking services (Inhorn 2004; Whittaker and Speier 2010). The anthropologist must rely on various intermediaries, depending on the circumstances. The two main brokers for the Czech Republic, IVF Holiday and IVF Choices, put me in contact with Czech clinics as well as former clients. Both brokers sent out a survey to past clients who had already traveled to the Czech Republic, which garnered thirty respondents. Many of these respondents agreed to a follow-up interview that took place during the fall of 2010. During the summers of 2010 and 2011, I conducted participant observation at two Moravian clinics, as well as at sites of lodging for North Americans (see figure I.1). I also interviewed Czech coordinators and doctors and North American patient-travelers. The town of Zlín (pronounced Zleen) is small, with a population of 80,000, offering one or two family-owned accommodations, whereas Brno (pronounced BIRno), the second-largest city in the Czech Republic, provides couples with various options, ranging from four-star hotels to apartment-like studios. North Americans in Brno are much more isolated from one another, un- Introduction | 11 like couples in Zlín, who often seek the comfort of other North Americans while abroad. I conducted a total of thirty preliminary surveys with former reproductive travelers and fifty interviews: twenty-nine with reproductive travelers (seventeen with women only, eleven with couples together, and one with a man only), ten with fertility brokers, and eleven with Czech clinic personnel. Because infertility is often considered a woman’s problem, and reproductive technologies are played out on women’s bodies, it was primarily women who were the more vocal informants. Sometimes I interviewed only the woman, or, if I interviewed the couple together, the woman usually had more to say. I interviewed only one husband and wife separately. From December 2011 to September 2012, I traveled to Canada and thirteen different states within the United States to follow up with patients I had met in the Czech Republic. I conducted a total of nineteen follow-up life history interviews with North American patients and brokers. In total, I met twenty-nine couples. My informants have made fifty-one total trips to the Czech Republic, and twenty-eight children have been born.3 Figure I.1. The favorite pension. 12 | Introduction Overwhelmingly, couples were very positive and willing to speak to me. They were happy to have another American to speak English with, particularly one who asked about their struggles. In the Czech Republic, I conducted interviews outside the North American–favored pension, in cafés and restaurants, in my room or their room, in the main lobby, at the local mall, or at the clinic (see figures I.2 and I.3). I shared many meals with American couples: breakfasts in the lobby of the pension or outside if the weather permitted and dinners at local favorite restaurants. I went to the town center, the local museum, the observation tower, and even the zoo, joining couples on their small excursions around town. During my final phase of research in North America, I met some couples at their favorite local restaurants in their hometowns, while others invited me into their homes. I shared cappuccinos or Little Caesar’s pizza and sweet tea with them. I maintain electronic communication with most, through either social media or e-mail. They keep me updated with news of their burgeoning families. Of course, I was not able to follow up with every couple that I met. Often those who suffer the pain of a failed cycle retreat to heal. As Throsby has shown in her study of failed cycles, “Those whose treatment fails literally drop out of the sight of the treatment providers” (2004:7). Figure I.2 The clinic waiting room. Introduction | 13 Fertility Vacationers Those traveling to the Czech Republic for fertility treatment are predominantly white, lower-class to middle-class North Americans. Two Canadian women are included in this research because gamete donors cannot be paid in Canada (which makes it difficult for those who need an egg donor to find one). Canadians who can afford treatment in the United States will generally travel south for treatment. However, those who cannot afford treatment in the United States will also travel to the Czech Republic. I encountered women whose husbands worked three jobs to provide for the entire family, working-class couples, and uppermiddle-class couples and women. The majority of reproductive travelers I met were from the lower middle class.4 The reproductive traveler is careful with her “fertility dollar,” a savvy consumer. Typically, North American reproductive travelers are in their late thirties or early forties, since the majority need IVF with an egg donor. Of thirty survey respondents, the average age was 40.3, with ages ranging from 27 to 53. They are from all over North America, including Florida, Georgia, South Carolina, Tennessee, Indiana, Illinois, Nebraska, WisFigure I.3 The operating room of the clinic. 14 | Introduction consin, Minnesota, California, Washington, and Texas. My respondents are mainly white, although I did interview one Puerto Rican couple and one African American couple. The majority of travelers are experienced in the world of ARTs, having undergone several IUIs in the United States, often with the help of fertility drugs. They may have even tried one or more IVF cycles before reaching the limits of their budget. North American reproductive tourists are relatively well traveled, although several were venturing abroad for the first time. Tracing Fertility Journeys This book traces North American fertility journeys, which can be considered a form of biological citizenship (Rose and Novas 2005). Rose claims that “conceptions of ‘biological citizenship’ have taken shape that recode the duties, rights, and expectations of human beings in relation to their sickness, and also to their life itself, reorganize the relations between individuals and their biomedical authorities, and reshape the ways in which human beings relate to themselves as ‘somatic individuals’” (2007:6). Petryna, who uses the label “biological citizenship” to capture collective and individual social practices of Ukrainians demanding social welfare within a democratizing, post-Soviet post-Chernobyl nation-state, considers the complex ways citizens “use biology, scientific knowledge and suffering to have access to cultural resources” under harsh market transitions (2003:3). Rose builds on this by noting that biological citizenship can take many forms (2007:25). One form is the patient support networks that develop online and abroad. While North Americans are not undergoing a harsh transition to a market economy, nor are they demanding social welfare; they are assuming responsibility for managing their own bodies and also assuming risk when they venture abroad for treatment. The book’s first chapter introduces North Americans who have been diagnosed with infertility and describes their reactions and the culturally meaningful ways they respond. Often, their responses are contradictory. There are particular stages of treatment using reproductive technologies, and this chapter traces these patients’ movement through the “baby business” in the United States (Spar 2006). Ultimately, the Introduction | 15 chapter ends with their alienation and disillusionment with overpriced treatment options. Chapter 2 follows North Americans who turn to various forms of social media as a way of learning about possible routes toward parenthood. It is on the Internet that they learn of reproductive travel to the Czech Republic and become diligent consumers conducting research. This chapter follows female patients as they enter virtual biosocial communities where they join online gendered support groups and engage in biomedical global citizenship. With the North American patients, we encounter IVF brokers who are packaging fertility holidays that promise a stress-free IVF cycle in a relaxing European setting. The marketing of fertility holidays online speaks to North American hopes, both for a child who resembles them and for the liberating aspects of travel (Löfgren 1999). In chapter 3 we witness the global encounters between North American patients and Czech doctors. The chapter uncovers the shifting role of the Czech clinics as they provide patient-centered care. I frame the entire industry as a global care route and trace global technologies, finance, images, and people enmeshed in “intimate labor” (Boris and Parreñas 2010). Czech fertility clinics are global checkout lanes for North American global biocitizens opting to purchase IVF with egg donation. Yet the economic nature of these transactions is minimized by affective discourse. The book continues in chapter 4 with a consideration of the social kinship bonds that are created and sustained at the local pension. At the same time, I deconstruct the fundamental contradictions embedded within “fertility holidays.” Women internalize the pressure to “relax” and treat their trip as a vacation in the hope of ensuring a successful pregnancy. Finally, chapter 5 follows North Americans as they return home, with or without a successful pregnancy. It traces the new difficulties many have with complicated pregnancies and raising multiples, and the sorrow of those who are not successful. It continues with an analysis of social kinship as it is sustained by women’s kin work via social media (di Leonardo 1987; Pande 2015). Essentially, social kinship networks of families with children born of egg donation in the Czech Republic continue

Mold on my Chutney! time to remove some mold on my mind !

Yesterday my wife was aghast when  i nonchalantly  put the  red tomato chutney i prepared almost a month ago and  kept in  a jar in the  refrigerator. she found some  bluish mold on the  inside of the  cap and wanted to throw  and  I wouldn't let her!
how bad of me  what kind of a cave man  I am to eat such food ?
this  led me to look up some  stuff on spoilage  yeasts and  molds.

some  interesting  facts .
this is  a copy of a blog post from

EURECKA brewing

https://eurekabrewing.wordpress.com/2014/02/10/hello-my-name-is-torulaspora-delbrueckii/


Hello, my name is Torulaspora delbrueckii


Eureka, we are back to science. Today, I would like to start with a series of posts covering various spoilage yeasts. The yeast of today is widely used in food production such as bread and bakery products but has a connection to beer as well. The yeast I am talking about is called Torulaspora delbrueckii. I stumbled upon T. delbrueckii a while ago as this yeast is apparently used in the production in Bavarian Wheat beers. However, I could not find any scientific reference discussing the use of Torulaspora in beer. The only published cases of T. delbrueckii in beer cover T. delbrueckii as spoilage organism.

Where do I work?

In general, all non-Saccharomyces yeasts are considered as spoilage yeasts associated with negative traits such as introducing off-flavors, impact on clarity and different sugar preferences leading to different attenuation levels (degree of fermentation). This is now changing and lots of efforts and research is put into examining the effects of different “spoilage” yeasts in either single inoculation or in mixed fermentations along with Saccharomyces cerevisiae, the working horse of most of the beer brewers, wine makers, spirit producers and lets not forget the bakers. One other “spoilage yeast” which gets a lot of attention lately is Brettanomyces for example.
The first positive effects of Torulaspora in mixed fermentations has been initially studied in wine where the use of Torulaspora increases the complexity of the final wines [Tataridis P, van Breda V, 2013]. And yeast products with this yeast are already available.

What about beer?

The first published evidence that Torulaspora has positive effects in beer was published by Tataridis et al in 2013. The authors fermented 3.5 L of malt extract wort (OG 1.044) each with WB-06 and a strain of Torulaspora delbrueckii and compared the beers. They first noticed that T. delbrueckii was capable of metabolizing maltose the most abundant sugar in wort. However, the fermentation using T. delbrueckii took a while longer to reach terminal gravity compared to the WB-06 fermentation (157 h vs 204 h). The beer fermented with T. delbrueckii was more hazy and had a higher terminal gravity (1.012 vs 1.009). Despite the higher terminal gravity and a slower fermentation activity, the most interesting differences could be observed in the final beers. T. delbrueckii showed higher ester notes (mainly banana, rose and bubblegum) and a decreased phenolic character than WB-06. Demonstrating that T. delbrueckii might have a potential positive role in the production of wheat beers.
Now that we covered some basics about the possible advantages of the yeast, lets look at the taxonomy and biochemistry.

A quick taxonomy journey

Questions to be addressed in this chapter are:
  1. What is the closest relative yeast of T. delbrueckii?
  2. How closely related are Saccharomyces cerevisiae and Dekkera bruxellensis (aka Brettanomyces bruxellensis) to T. delbrueckii?
To address these questions, one can look at certain DNA sequences of the different yeasts and compare them in terms of how similar they are. I will try to make this very simple here. Think of a mother yeast cell from which all existing yeasts originate and evolved during time. Kind of the ur-mother-yeast-cell. Lets assign the letter A to the mother yeast cell and B to be a yeast daughter cell of A. Let me walk you through some possible examples of B and its impact on the DNA compared to A. Please notice that this is a simplified version and I am fully aware that biology is a bit more complicated than depicted in this example.
  • B is a direct ancestor of A. B is a daughter cell of A and originates from a budding/fission event of A directly creating B. In this example, the DNA of both cells are the same (I intentionally leave mutations etc aside here)
  • B is an ancestor of A but not a direct one and evolved during time thereby changing the DNA sequences in B compared to A. B is still in the lineage of A but not very close any more due to evolutionary events. There can be several billion, billion, billion daughter cells between A and B. In general, more similar DNA sequences are more likely to be closer related
  • If B is very distant of A (in terms of DNA similarities), B is classified as separate species than A. In this case, B and A cannot interbreed any more because they are too distant of each others. S. cerevisiae and Dekkera for example would be daughter cells of A but very distant and form their own species
Lets take another example, horses. Zebra, horses and donkeys look very alike but are different species. (I intentionally leave mules aside here as this these animals are hybrids of horse and donkeys). It is very likely that all these species originate from some kind of ur-horse but individually adapted to new environments forming three different, new animals. To investigate which animal is closer related to which one, one could isolate DNA from the three animals and compare them.
To address what the relationship between T. delbrueckii and S. cerevisiae and Dekkera is, one can look at the large subunit of the ribosome (LSU rRNA). The ribosome is a complex of various subunits and is responsible for the protein synthesis in the cell. Because the ribosome is a very important machinery in a cell, the changes over time on the DNA level which encode parts of the ribosome are rather low. And can therefore be used to assess relationships among different species and strains. For T. delbrueckii, the relationship between some other yeasts is depicted in Fig 1 as a phylogeny tree. The tree begins with a common ancestor and the branches represent different fates.
Phylo_tree_torulaspora
Fig 1: Phylogeny tree of Torulaspora relatives based on LSU rRNA created using Phylogeny.fr
I included additional members from the Torulaspora genus to have some close relatives of T. delbrueckii in the tree. And Saccharomyces and Dekkera to see how they end up in the phylogeny tree. One can observe that S. cerevisiae seems to be closer to Torulaspora than Dekkera.
Addressing the closest yeast relative of Torulaspora delbrueckii is a bit more complicated. First of all, it all depends on the data one uses to construct the phylogeny trees. If you for example do not include the true closest yeast relative in the dataset you will not pick it up anyway. Looking through some published phylogeny trees makes it hard to give a final answer. In one example published by Kurtzman et al (2011), the closest relative of T. delbrueckii is S. cerevisiae (like shown in Fig 1). On the other hand, another phylogeny tree published by Kurtzman et al (2011) ends up grouping Zygotorulaspora and Zygosaccharomyces closer to Torulaspora than the Saccharomyces group. In the latter case, Zygosaccharomyces mrakii and Z. rouxii end up being the closest relatives. It is therefore not possible to give a final answer here based on my investigations. However, what is obvious from the phylogeny tree shown in Fig 1, Dekkera is farther apart from Torulaspora than Saccharomyces.
Torulaspora delbrueckii has a very long list of synonyms which include a lot of different genera like SaccharomycesDebaryomycesZygosaccharomyces and Torulaspora. In 1970, Kurtzman et al assigned Torulaspora and Zygosaccharomyces to Saccharomyces leaving Debaryomyces as a separate species. Five years later, van der Walt and Johannsen recreated the genus Torulaspora and incorporated all Debaryomyces species to it as well. Nine years later, Kurtzman et al accepted all four species again. This is actually not very uncommon in yeast taxonomy which is why yeast taxonomy can be very confusing and undergo lots of changes.
One reason why SaccharomycesDebaryomycesZygosaccharomyces and Torulaspora make the lives of taxonomists so hard is their biochemical and phenotypical similarities and behaviour. Thus making it hard to differentiate the species. In addition, different yeasts were initially assigned to species based on morphology and biochemical properties. Nowadays, yeasts are assigned to species based on DNA. Which can lead to a lot of taxonomical changes and re-assignments of various yeasts. That’s how it is.
Beside T. delbrueckii, five other Torulaspora species exist being T. globosaT. franciscaeT. globosa, T. maleeaeT. microellipsoides and T. pretoriensis. All other species with the exception of T. microellipsoides and T. delbrueckii are not associated with beverages. T. microellipsoides could be isolated from apple juice, tea-beer and lemonade and is a contaminant of soft drinks [Kutzman et al, 2011].

Where can you find me?

Most of the Torulaspora species and strains are isolated from soil, fermenting grapes (wine), berries, agave juice, tea-beer, apple juice, leaf of mangrove tree, moss, lemonade and tree barks [Kutzman et al, 2011]. With a bit of luck, you may find yourself some Torulaspora or you may go with the available Torulaspora delbrueckii yeast products.
Some say that Wyeast’s WY3068 Weihenstephan is a Torulaspora delbrueckii strain or contains Torulaspora delbrueckii. At least based on micrographs, its hard to tell whether WY3068 Weihenstephan is different from a typical Ale yeast (such as WY1056 American Ale) (Fig 2, 3). If anyone has rRNA seqs from WY3068, please let me know.
WY3068
Fig 2: Wyeast 3068 Weihenstephan
WY1056
Fig 3: Wyeast 1056 American Ale

Some biochemical stats about me for yeast ranchers

Below a summary of the biochemical properties of T. delbrueckii. Data is summarized from Kutzman et al (2011). One way of differentiating between S. cerevisiae and T. delbrueckii can be performed using RFLP using HinfI on amplified ITS1-5.8S-ITS2 amplicons [van Breda, 2013]. Or obviously by sequencing the ITS1-5.8S-ITS2 amplicons.
Systematic name:Torulaspora delbrueckii
Synonyms:There are a lots of accepted synonyms for this yeasts. Just some examples: Saccharomyces delbrueckii, S. rosei, S. fermentati, S. torulosus, S. chevalieri, S. vafer, S. saitoanus, S. florenzani
Growth in malt extract:Cell morphology:Spherical, ellipsoidal, 2-6 µm x 6.6 µm
Clustering:Occurring as single cells or in pairs
Pseudohyphae:None
Pellicle formation:None
Growth in malt extract:Colony morphology:After 3 days: Butyrous, dull to glistening, and tannish-white in color
Fermentation:Glucose:Positive
Galactose:Variable
Sucrose:Variable
Maltose:Variable
Lactose:Negativ
Raffinose:Variable
Trehalose:Variable
That’s all about Torulaspora delbrueckii so far. I hope this was in a way informative to you. At least keep in mind that spoilage yeasts do not inevitably have to be bad. If one can use their potential for our advantage, we can make something really unique. Have fun playing around with Torulaspora delbrueckii.

Bibliography

  • Kurtzman CP, Fell JW, Boekhout T (2011The Yeasts, a Taxonomic Study. Volume 1. Fifth edition. Elsevier (Link to sciencedirect)
  • Tataridis P, Kanelis A, Logotetis S, Nerancis E (2013Use of non-saccharomyces Torulaspora delbrueckii yeast strains in winemaking and brewing. Zbornik Matice srpske za prirodne nauke, Vol 124, 415-426
  • van Breda V., Jolly N, van Wyk J (2013Characterisation of commercial and natural Torulaspora delbrueckii wine yeast strains. International Journal of Food Microbiology, 163, 80-88